These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 23147077

  • 21. Aryl amide derivatives of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives useful as ASK1 inhibitors, an evaluation of WO2012080735.
    Norman P.
    Expert Opin Ther Pat; 2012 Dec; 22(12):1479-83. PubMed ID: 22917158
    [Abstract] [Full Text] [Related]

  • 22. The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors.
    Buckmelter AJ, Ren L, Laird ER, Rast B, Miknis G, Wenglowsky S, Schlachter S, Welch M, Tarlton E, Grina J, Lyssikatos J, Brandhuber BJ, Morales T, Randolph N, Vigers G, Martinson M, Callejo M.
    Bioorg Med Chem Lett; 2011 Feb 15; 21(4):1248-52. PubMed ID: 21211972
    [Abstract] [Full Text] [Related]

  • 23. Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitors.
    Lovering F, Morgan P, Allais C, Aulabaugh A, Brodfuehrer J, Chang J, Coe J, Ding W, Dowty H, Fleming M, Frisbie R, Guzova J, Hepworth D, Jasti J, Kortum S, Kurumbail R, Mohan S, Papaioannou N, Strohbach JW, Vincent F, Lee K, Zapf CW.
    Eur J Med Chem; 2018 Feb 10; 145():606-621. PubMed ID: 29348070
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Novel imidazo[1,2-a]pyridine based inhibitors of the IGF-1 receptor tyrosine kinase: optimization of the aniline.
    Ducray R, Jones CD, Jung FH, Simpson I, Curwen J, Pass M.
    Bioorg Med Chem Lett; 2011 Aug 15; 21(16):4702-4. PubMed ID: 21764307
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.
    Wenglowsky S, Moreno D, Laird ER, Gloor SL, Ren L, Risom T, Rudolph J, Sturgis HL, Voegtli WC.
    Bioorg Med Chem Lett; 2012 Oct 01; 22(19):6237-41. PubMed ID: 22954737
    [Abstract] [Full Text] [Related]

  • 28. Synthesis of 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5-phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents.
    Jacquemard U, Dias N, Lansiaux A, Bailly C, Logé C, Robert JM, Lozach O, Meijer L, Mérour JY, Routier S.
    Bioorg Med Chem; 2008 May 01; 16(9):4932-53. PubMed ID: 18439832
    [Abstract] [Full Text] [Related]

  • 29. Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis.
    Kim O, Jeong Y, Lee H, Hong SS, Hong S.
    J Med Chem; 2011 Apr 14; 54(7):2455-66. PubMed ID: 21388141
    [Abstract] [Full Text] [Related]

  • 30. Discovery of 3H-imidazo[4,5-b]pyridines as potent c-Met kinase inhibitors: design, synthesis, and biological evaluation.
    Chen D, Wang Y, Ma Y, Xiong B, Ai J, Chen Y, Geng M, Shen J.
    ChemMedChem; 2012 Jun 14; 7(6):1057-70. PubMed ID: 22581753
    [Abstract] [Full Text] [Related]

  • 31. Synthesis and biological evaluation of a triazole-based library of pyrido[2,3-d]pyrimidines as FGFR3 tyrosine kinase inhibitors.
    Le Corre L, Girard AL, Aubertin J, Radvanyi F, Benoist-Lasselin C, Jonquoy A, Mugniery E, Legeai-Mallet L, Busca P, Le Merrer Y.
    Org Biomol Chem; 2010 May 07; 8(9):2164-73. PubMed ID: 20401393
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities.
    Xi JB, Fang YF, Frett B, Zhu ML, Zhu T, Kong YN, Guan FJ, Zhao Y, Zhang XW, Li HY, Ma ML, Hu W.
    Eur J Med Chem; 2017 Jan 27; 126():1083-1106. PubMed ID: 28039836
    [Abstract] [Full Text] [Related]

  • 34. Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.
    Pastor J, Oyarzabal J, Saluste G, Alvarez RM, Rivero V, Ramos F, Cendón E, Blanco-Aparicio C, Ajenjo N, Cebriá A, Albarrán MI, Cebrián D, Corrionero A, Fominaya J, Montoya G, Mazzorana M.
    Bioorg Med Chem Lett; 2012 Feb 15; 22(4):1591-7. PubMed ID: 22266039
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 1.
    Kaieda A, Takahashi M, Fukuda H, Okamoto R, Morimoto S, Gotoh M, Miyazaki T, Hori Y, Unno S, Kawamoto T, Tanaka T, Itono S, Takagi T, Sugimoto H, Okada K, Snell G, Bertsch R, Nguyen J, Sang BC, Miwatashi S.
    ChemMedChem; 2019 May 17; 14(10):1022-1030. PubMed ID: 30945818
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Discovery and optimization of a series of 2-aminothiazole-oxazoles as potent phosphoinositide 3-kinase γ inhibitors.
    Oka Y, Yabuuchi T, Fujii Y, Ohtake H, Wakahara S, Matsumoto K, Endo M, Tamura Y, Sekiguchi Y.
    Bioorg Med Chem Lett; 2012 Dec 15; 22(24):7534-8. PubMed ID: 23122859
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.